DMAC logo

DiaMedica Therapeutics (DMAC) Cash From Operations

Annual CFO

-$18.73 M
-$7.22 M-62.70%

December 31, 2023

Summary

Performance

1-Year Change

-62.7%

3-Year Change

-103.9%

5-Year Change

-228.79%

15-Year Change

-380.21%

DMAC Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

48%
DMAC annual cash flow from operations is higher than 48% of companies in Healthcare sector

High & Low

All-time High

-$99.40 K

3-Year Low

-$18.73 M
DMAC annual cash flow from operations is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
DMAC previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Mar 20, 2025
DMAC next annual earnings announcement is scheduled for Mar 20, 2025

OtherDMACcash flowmetrics:

Annual CFI

-$18.30 M
DMAC annual cash flow from investing activities is -$18.30 million

Annual CFF

$36.84 M
DMAC annual cash flow from financing activities is $36.84 million

Annual FCF

-$18.75 M
DMAC annual free cash flow is -$18.75 million

Annual CAPEX

-
DMAC annual capital expenditures value is unknown

Quarterly CFO

-$4.47 M
+$49.00 K+1.08%

September 30, 2024

Summary

Performance

3-Month Change

+1.08%

1-Year Change

+6.82%

3-Year Change

-46.75%

5-Year Change

-46.75%

DMAC Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

46.46%
DMAC quarterly cash flow from operations is higher than 46.46% of companies in Healthcare sector

High & Low

All-time High

$372.20 K
DMAC quarterly cash flow from operations is currently -1300.97% below its historical high of $372.20 thousand

3-Year Low

-$6.65 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
DMAC previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 20, 2025
DMAC next earnings announcement is scheduled for Mar 20, 2025

OtherDMACcash flowmetrics:

Quarterly CFI

-$5.58 M
DMAC quarterly cash flow from investing activities is -$5.58 million

Quarterly CFF

$123.00 K
DMAC quarterly cash flow from financing activities is $123.00 thousand

Quarterly FCF

-$4.48 M
DMAC quarterly free cash flow is -$4.48 million

Quarterly CAPEX

-
DMAC quarterly capital expenditures value is unknown

TTM CFO

-$19.45 M
+$327.00 K+1.65%

September 30, 2024

Summary

Performance

3-Month Change

+1.65%

1-Year Change

-10.02%

3-Year Change

-56.08%

5-Year Change

-56.08%

DMAC TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

45.85%
DMAC TTM cash flow from operations is higher than 45.85% of companies in Healthcare sector

High & Low

All-time High

-$147.90 K

3-Year Low

-$20.29 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
DMAC previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 20, 2025
DMAC next earnings announcement is scheduled for Mar 20, 2025

OtherDMACcash flowmetrics:

TTM CFI

$9.48 M
DMAC TTM cash flow from investing activities is $9.48 million

TTM CFF

$11.87 M
DMAC TTM cash flow from financing activities is $11.87 million

TTM FCF

-$19.48 M
DMAC TTM free cash flow is -$19.48 million

TTM CAPEX

-
DMAC TTM capital expenditures value is unknown

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

DMAC Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-62.7%+6.8%-10.0%
3 y3 years-103.9%-46.8%-56.1%
5 y5 years-228.8%-46.8%-56.1%

DMAC Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-62.7%at low-89.3%+32.8%-69.0%+4.1%
5 y5-year-105.8%at low-429.6%+32.8%-181.2%+4.1%
alltimeall time<-9999.0%at low-1301.0%+32.8%<-9999.0%+4.1%

DiaMedica Therapeutics Cash From Operations History

DateAnnualQuarterlyTTM
Sep 2024
-
-$4.47 M(-1.1%)
-$19.45 M(-1.7%)
Jun 2024
-
-$4.52 M(-32.1%)
-$19.78 M(-2.5%)
Mar 2024
-
-$6.65 M(+74.5%)
-$20.29 M(+8.4%)
Dec 2023
-$18.73 M(+62.7%)
-$3.81 M(-20.5%)
-$18.73 M(+5.9%)
Sep 2023
-
-$4.80 M(-4.6%)
-$17.68 M(+16.0%)
Jun 2023
-
-$5.03 M(-1.2%)
-$15.25 M(+19.9%)
Mar 2023
-
-$5.09 M(+84.0%)
-$12.71 M(+10.4%)
Dec 2022
-$11.51 M(-6.0%)
-$2.77 M(+17.2%)
-$11.51 M(-0.3%)
Sep 2022
-
-$2.36 M(-5.4%)
-$11.55 M(-5.6%)
Jun 2022
-
-$2.50 M(-35.8%)
-$12.23 M(+3.4%)
Mar 2022
-
-$3.89 M(+38.7%)
-$11.83 M(-3.5%)
Dec 2021
-$12.25 M(+33.4%)
-$2.80 M(-7.9%)
-$12.25 M(-1.7%)
Sep 2021
-
-$3.05 M(+45.8%)
-$12.46 M(+5.9%)
Jun 2021
-
-$2.09 M(-51.6%)
-$11.77 M(+11.8%)
Mar 2021
-
-$4.31 M(+43.0%)
-$10.52 M(+14.5%)
Dec 2020
-$9.19 M(+0.9%)
-$3.02 M(+28.5%)
-$9.19 M(+14.3%)
Sep 2020
-
-$2.35 M(+178.1%)
-$8.03 M(+16.1%)
Jun 2020
-
-$844.00 K(-71.7%)
-$6.92 M(-22.7%)
Mar 2020
-
-$2.98 M(+59.7%)
-$8.95 M(-1.7%)
Dec 2019
-$9.10 M(+59.8%)
-$1.86 M(+51.4%)
-$9.10 M(-0.4%)
Sep 2019
-
-$1.23 M(-57.1%)
-$9.14 M(-6.2%)
Jun 2019
-
-$2.87 M(-8.4%)
-$9.74 M(+23.4%)
Mar 2019
-
-$3.13 M(+64.9%)
-$7.89 M(+38.6%)
Dec 2018
-$5.70 M(+46.1%)
-$1.90 M(+3.4%)
-$5.70 M(+19.4%)
Sep 2018
-
-$1.84 M(+79.7%)
-$4.77 M(+32.1%)
Jun 2018
-
-$1.02 M(+9.4%)
-$3.61 M(-10.0%)
Mar 2018
-
-$935.00 K(-4.1%)
-$4.01 M(+2.9%)
Dec 2017
-$3.90 M(+30.6%)
-$974.80 K(+43.6%)
-$3.90 M(-7.0%)
Sep 2017
-
-$679.00 K(-52.3%)
-$4.19 M(-5.7%)
Jun 2017
-
-$1.42 M(+72.8%)
-$4.44 M(+30.1%)
Mar 2017
-
-$823.20 K(-35.0%)
-$3.42 M(+14.4%)
Dec 2016
-$2.99 M(+91.1%)
-$1.27 M(+36.1%)
-$2.99 M(+32.0%)
Sep 2016
-
-$930.90 K(+135.9%)
-$2.26 M(+49.4%)
Jun 2016
-
-$394.60 K(+0.1%)
-$1.51 M(-6.4%)
Mar 2016
-
-$394.20 K(-27.4%)
-$1.62 M(+3.5%)
Dec 2015
-$1.56 M
-$543.00 K(+197.9%)
-$1.56 M(+36.6%)
Sep 2015
-
-$182.30 K(-63.5%)
-$1.14 M(-66.5%)
DateAnnualQuarterlyTTM
Jun 2015
-
-$498.80 K(+47.1%)
-$3.41 M(+15.5%)
Mar 2015
-
-$339.20 K(+173.1%)
-$2.95 M(-21.3%)
Dec 2014
-$3.76 M(-31.7%)
-$124.20 K(-94.9%)
-$3.76 M(-8.1%)
Sep 2014
-
-$2.45 M(+5861.8%)
-$4.09 M(+48.2%)
Jun 2014
-
-$41.10 K(-96.4%)
-$2.76 M(-42.3%)
Mar 2014
-
-$1.14 M(+149.9%)
-$4.78 M(-13.1%)
Dec 2013
-$5.50 M(+0.3%)
-$456.10 K(-59.3%)
-$5.50 M(-15.2%)
Sep 2013
-
-$1.12 M(-45.7%)
-$6.49 M(-11.4%)
Jun 2013
-
-$2.06 M(+11.0%)
-$7.32 M(+10.0%)
Mar 2013
-
-$1.86 M(+28.8%)
-$6.66 M(+21.5%)
Dec 2012
-$5.48 M(+59.6%)
-$1.44 M(-26.2%)
-$5.48 M(+3.6%)
Sep 2012
-
-$1.96 M(+39.7%)
-$5.29 M(+27.6%)
Jun 2012
-
-$1.40 M(+104.8%)
-$4.15 M(+19.8%)
Mar 2012
-
-$683.80 K(-45.4%)
-$3.46 M(+0.7%)
Dec 2011
-$3.44 M(+44.6%)
-$1.25 M(+54.3%)
-$3.44 M(+26.7%)
Sep 2011
-
-$811.50 K(+13.8%)
-$2.71 M(+77.4%)
Jun 2011
-
-$713.40 K(+8.2%)
-$1.53 M(-44.1%)
Mar 2011
-
-$659.30 K(+24.8%)
-$2.73 M(+15.0%)
Dec 2010
-$2.38 M(+10.7%)
-$528.10 K(-241.9%)
-$2.38 M(+2.0%)
Sep 2010
-
$372.20 K(-119.4%)
-$2.33 M(-28.9%)
Jun 2010
-
-$1.92 M(+532.9%)
-$3.28 M(+65.0%)
Mar 2010
-
-$303.00 K(-37.2%)
-$1.99 M(-7.5%)
Dec 2009
-$2.15 M(+46.4%)
-$482.30 K(-16.0%)
-$2.15 M(+21.9%)
Sep 2009
-
-$574.00 K(-8.4%)
-$1.76 M(-8.7%)
Jun 2009
-
-$626.70 K(+35.2%)
-$1.93 M(-0.3%)
Mar 2009
-
-$463.70 K(+379.5%)
-$1.93 M(+31.9%)
Dec 2008
-$1.47 M(+20.9%)
-$96.70 K(-87.0%)
-$1.47 M(-7.0%)
Sep 2008
-
-$741.30 K(+17.3%)
-$1.58 M(+3.4%)
Jun 2008
-
-$631.80 K(<-9900.0%)
-$1.53 M(+43.6%)
Mar 2008
-
$3400.00(-101.6%)
-$1.06 M(-12.5%)
Dec 2007
-$1.21 M(+51.4%)
-$207.40 K(-69.9%)
-$1.21 M(+20.6%)
Sep 2007
-
-$689.80 K(+309.9%)
-$1.01 M(+218.2%)
Jun 2007
-
-$168.30 K(+13.8%)
-$316.20 K(+113.8%)
Mar 2007
-
-$147.90 K
-$147.90 K
Dec 2006
-$801.20 K(-3.6%)
-
-
Dec 2005
-$831.20 K(+736.2%)
-
-
Dec 2004
-$99.40 K
-
-

FAQ

  • What is DiaMedica Therapeutics annual cash flow from operations?
  • What is the all time high annual CFO for DiaMedica Therapeutics?
  • What is DiaMedica Therapeutics annual CFO year-on-year change?
  • What is DiaMedica Therapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for DiaMedica Therapeutics?
  • What is DiaMedica Therapeutics quarterly CFO year-on-year change?
  • What is DiaMedica Therapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for DiaMedica Therapeutics?
  • What is DiaMedica Therapeutics TTM CFO year-on-year change?

What is DiaMedica Therapeutics annual cash flow from operations?

The current annual CFO of DMAC is -$18.73 M

What is the all time high annual CFO for DiaMedica Therapeutics?

DiaMedica Therapeutics all-time high annual cash flow from operations is -$99.40 K

What is DiaMedica Therapeutics annual CFO year-on-year change?

Over the past year, DMAC annual cash flow from operations has changed by -$7.22 M (-62.70%)

What is DiaMedica Therapeutics quarterly cash flow from operations?

The current quarterly CFO of DMAC is -$4.47 M

What is the all time high quarterly CFO for DiaMedica Therapeutics?

DiaMedica Therapeutics all-time high quarterly cash flow from operations is $372.20 K

What is DiaMedica Therapeutics quarterly CFO year-on-year change?

Over the past year, DMAC quarterly cash flow from operations has changed by +$327.00 K (+6.82%)

What is DiaMedica Therapeutics TTM cash flow from operations?

The current TTM CFO of DMAC is -$19.45 M

What is the all time high TTM CFO for DiaMedica Therapeutics?

DiaMedica Therapeutics all-time high TTM cash flow from operations is -$147.90 K

What is DiaMedica Therapeutics TTM CFO year-on-year change?

Over the past year, DMAC TTM cash flow from operations has changed by -$1.77 M (-10.02%)